Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Browse
New in RUL
About RUL
In numbers
Help
Sign in
Cannabinoids and triple-negative breast cancer treatment
ID
Dobovišek, Luka
(
Author
),
ID
Borštnar, Simona
(
Author
),
ID
Debeljak, Nataša
(
Author
),
ID
Kranjc Brezar, Simona
(
Author
)
PDF - Presentation file,
Download
(1,10 MB)
MD5: DA666E120BC28ACBE07BF76A7E32A232
URL - Source URL, Visit
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1386548/full
Image galllery
Abstract
Triple-negative breast cancer (TNBC) accounts for about 10-20% of all breast cancer cases and is associated with an unfavorable prognosis. Until recently, treatment options for TNBC were limited to chemotherapy. A new successful systemic treatment is immunotherapy with immune checkpoint inhibitors, but new tumor-specific biomarkers are needed to improve patient outcomes. Cannabinoids show antitumor activity in most preclinical studies in TNBC models and do not appear to have adverse effects on chemotherapy. Clinical data are needed to evaluate efficacy and safety in humans. Importantly, the endocannabinoid system is linked to the immune system and immunosuppression. Therefore, cannabinoid receptors could be a potential biomarker for immune checkpoint inhibitor therapy or a novel mechanism to reverse resistance to immunotherapy. In this article, we provide an overview of the currently available information on how cannabinoids may influence standard therapy in TNBC.
Language:
English
Keywords:
triple-negative breast cancer
,
breast cancer
,
cancer treatment
,
cannabinoids
Work type:
Article
Typology:
1.02 - Review Article
Organization:
MF - Faculty of Medicine
Publication version:
Version of Record
Publication date:
01.08.2024
Year:
2024
Number of pages:
Str. 1-13
Numbering:
Vol. 15
PID:
20.500.12556/RUL-165016
UDC:
618.1
ISSN on article:
1664-3224
DOI:
10.3389/fimmu.2024.1386548
COBISS.SI-ID:
204044547
Publication date in RUL:
21.11.2024
Views:
53
Downloads:
5
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
Frontiers in immunology
Shortened title:
Front. immunol.
Publisher:
Frontiers Research Foundation
ISSN:
1664-3224
COBISS.SI-ID:
30774233
Licences
License:
CC BY 4.0, Creative Commons Attribution 4.0 International
Link:
http://creativecommons.org/licenses/by/4.0/
Description:
This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Secondary language
Language:
Slovenian
Keywords:
trojno negativni rak dojke
,
rak dojke
,
onkološko zdravljenje
,
kanabinoidi
Projects
Funder:
ARIS - Slovenian Research and Innovation Agency
Project number:
P3-0003-2022
Name:
Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev
Funder:
ARIS - Slovenian Research and Innovation Agency
Project number:
J3-3062-2021
Name:
Avtologni imunohibridomi in napredno zdravljenje trojno negativnega raka dojk stadijev II in III
Funder:
ARIS - Slovenian Research and Innovation Agency
Project number:
L3-9279
Funder:
ARIS - Slovenian Research and Innovation Agency
Project number:
L3-4511
Funder:
ARIS - Slovenian Research and Innovation Agency
Project number:
PI-0390
Funder:
Other - Other funder or multiple funders
Funding programme:
University Medical Center Ljubljana
Project number:
20170073
Funder:
Other - Other funder or multiple funders
Funding programme:
University Medical Centre Ljubljana
Project number:
20200231
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back